Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 17/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21948921 | 0.93 | TYK2 (0.48) | TYK2MTNR1AMTNR1BKDM4EALDH1A1 | |
| SCHEMBL21948924 | 0.88 | TYK2 (0.72) | TYK2 | |
| SCHEMBL21963456 | 0.88 | TYK2 (0.72) | TYK2 | |
| SCHEMBL20689041 | 0.87 | TYK2 (0.58) | TYK2 | |
| SCHEMBL21948055 | 0.85 | TYK2 (0.51) | TYK2KDM4EALDH1A1HTTNPSR1 | |
| SCHEMBL21285359 | 0.85 | CA12 (0.46) | TYK2KDM4EALDH1A1HTTNPSR1 | |
| SCHEMBL20689333 | 0.84 | TYK2 (0.49) | TYK2KDM4EALDH1A1HTTNPSR1 | |
| SCHEMBL20689457 | 0.84 | TYK2 (0.52) | TYK2KDM4EALDH1A1HTTNPSR1 | |
| SCHEMBL21258520 | 0.83 | TYK2 (0.56) | TYK2KDM4EALDH1A1 | |
| SCHEMBL20689592 | 0.82 | TYK2 (0.67) | TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-30 | — | — | US | disclosed |
| WO-2020081508-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TYK2 1/4885MTNR1A 3366/4885MTNR1B 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.